Beximco Pharmaceuticals PLC (AIM: BXP), the Bangladesh-based generic medicines manufacturer and active pharmaceutical ingredients producer, has reported audited full-year results for the year ended 30 June 2026, disclosing net revenue of BDT 56,265.9m (£347.5m) and profit after tax of BDT 9,160.8m (£56.6m). The company achieved double-digit growth across both its domestic and export sales, while completing new product registrations in 18 countries. Investors will also note the board's recommendation of a 60% cash dividend of BDT 6.00 per share, alongside a rising net asset value per share of BDT 139.18.

Key Points

  • Beximco Pharmaceuticals PLC (AIM: BXP), LEI No.: 213800IMBBD6TIOQGB56
  • Net revenue grew 14.5% to BDT 56,265.9m (£347.5m) for the year ended 30 June 2026, with profit after tax rising 30.9% to BDT 9,160.8m (£56.6m)
  • EPS of BDT 20.17 (up from BDT 15.56); 60% cash dividend of BDT 6.00 per share recommended; NAV per share rose to BDT 139.18 from BDT 119.04
  • Investors may be watching the progress of international product launches — including the Triko cystic fibrosis generic — and how the company navigates ongoing global macro-economic pressures

Beximco Pharma Revenue Climbs to £347.5m as Domestic Sales Lead Growth in FY2026

The announcement states that consolidated net revenue increased 14.5% year-on-year, reaching BDT 56,265.9m (£347.5m) compared with BDT 49,120.4m (£295.6m) in the prior year. Domestic sales, which represent the larger portion of revenues, rose 15.1% to BDT 51,852.5m (£320.3m), while export sales grew 8.3% to BDT 4,413.4m (£27.3m). Profit after tax climbed 30.9% to BDT 9,160.8m (£56.6m), with earnings per share advancing to BDT 20.17 from BDT 15.56. Net operating cash flows per share also improved to BDT 21.33 from BDT 16.19 in the prior year, the results show.

Triko Cystic Fibrosis Generic Handed to Patients Across Six Countries in Landmark Launch

A highlight of the operational period was the handover of Triko — described in the announcement as the world's first and only generic copy of breakthrough cystic fibrosis drug Trikafta — to patients from six countries. Managing Director Iqbal Ahmed stated in the announcement that this launch "strongly reflects our commitment to ensuring that patients around the world have access to affordable and high-quality medicines." The company also launched anti-migraine drug Eletriptan tablets in the United States and Sotalol tablets in Canada, commenced exports to Lebanon, and completed 43 new registrations of 36 products across 18 countries during the period.

60% Cash Dividend Recommended as NAV Per Share Rises to BDT 139.18

The board has recommended a 60% cash dividend equivalent to BDT 6.00 per share for the financial year. Total shareholders' equity increased to BDT 62,091.2m as at 30 June 2026 from BDT 53,107.1m a year earlier, with net asset value per share rising to BDT 139.18 compared with BDT 119.04 at the close of the prior period. Cash and cash equivalents also strengthened markedly, reaching BDT 6,668.0m from BDT 1,700.1m at the previous year-end, suggesting an improvement in the company's liquidity position over the reporting period.

Post-Period Activity and Scrip Awards Nomination Signal Continued Pipeline Development

Since the period end, Beximco Pharma states it has launched five generics in six presentations in Bangladesh — two of which are described as firsts for the country — and completed nine registrations of eight products across six countries. The company has also been nominated for The Scrip Awards 2026 in the Community Partnership of the Year category. Beximco Pharma, which employs more than 6,000 people and operates manufacturing facilities certified by regulatory authorities across the USA, Europe, Australia, Canada, and other regions, maintains a geographic footprint in more than 50 countries, the announcement confirms.